JP Morgan Chase
HRTX icon

JP Morgan Chase’s Heron Therapeutics HRTX Stock Holding History

JP Morgan Chase’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-200
Closed -$3K – 5595
2020
Q2 		$3K Buy
+200
New +$3.29K ﹤0.01% 5233
2018
Q3 		– Sell
-220,000
Closed -$8.55M – 5729
2018
Q2 		$8.55M Buy
+220,000
New +$7M ﹤0.01% 2265

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
CC
Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return

JP Morgan Chase's HRTX Position: Q2 2026 in Review

JP Morgan Chase increased its Heron Therapeutics (HRTX) stake by 16% in Q2 2026, buying an estimated $8.47K and bringing the position to 75,665 shares worth $33K. The position accounts for ﹤0.01% of the portfolio, ranked #6585.

JP Morgan Chase first reported a position in HRTX in Q4 2014 and has held it in 45 quarters since. The position peaked at $70M in Q2 2021. 163 funds tracked by Wall St. Rank hold HRTX as of Q2 2026.

  • JP Morgan Chase held 75,665 shares of Heron Therapeutics worth $33K as of Q2 2026.
  • JP Morgan Chase bought 10,559 Heron Therapeutics shares in Q2 2026, an estimated $8.47K.
  • Heron Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #6585 holding.
  • JP Morgan Chase first reported a position in Heron Therapeutics in Q4 2014 and has held it in 45 quarters since.
  • JP Morgan Chase's Heron Therapeutics position peaked at $70M in Q2 2021.
  • 163 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.